Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

Sean WhartonThomas BlevinsLisa ConneryJulio RosenstockSohini RahaRong LiuXiaosu MaKieren J MatherAxel HauptDeborah RobinsEdward PrattChristof KazdaManige Konignull null

Published in: The New England journal of medicine (2023)

Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. (Funded by Eli Lilly; GZGI ClinicalTrials.gov number, NCT05051579.).

Keyphrases

physical activity
weight loss
weight gain
metabolic syndrome
insulin resistance
body mass index
type diabetes
body weight